136 related articles for article (PubMed ID: 20080680)
1. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.
Sarafraz-Yazdi E; Bowne WB; Adler V; Sookraj KA; Wu V; Shteyler V; Patel H; Oxbury W; Brandt-Rauf P; Zenilman ME; Michl J; Pincus MR
Proc Natl Acad Sci U S A; 2010 Feb; 107(5):1918-23. PubMed ID: 20080680
[TBL] [Abstract][Full Text] [Related]
2. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.
Davitt K; Babcock BD; Fenelus M; Poon CK; Sarkar A; Trivigno V; Zolkind PA; Matthew SM; Grin'kina N; Orynbayeva Z; Shaikh MF; Adler V; Michl J; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2014; 44(3):241-8. PubMed ID: 25117093
[TBL] [Abstract][Full Text] [Related]
3. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.
Krzesaj P; Adler V; Feinman RD; Miller A; Silberstein M; Yazdi E; Pincus MR
Ann Clin Lab Sci; 2024 Mar; 54(2):137-148. PubMed ID: 38802154
[TBL] [Abstract][Full Text] [Related]
4. Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes.
Thadi A; Gleeson EM; Khalili M; Shaikh MF; Goldstein E; Morano WF; Daniels LM; Grandhi N; Glatthorn H; Richard SD; Campbell PM; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2020 Sep; 50(5):611-624. PubMed ID: 33067207
[TBL] [Abstract][Full Text] [Related]
5. Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.
Thadi A; Lewis L; Goldstein E; Aggarwal A; Khalili M; Steele L; Polyak B; Seydafkan S; Bluth MH; Ward KA; Styler M; Campbell PM; Pincus MR; Bowne WB
Anticancer Res; 2020 Sep; 40(9):4857-4867. PubMed ID: 32878773
[TBL] [Abstract][Full Text] [Related]
6. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.
Sookraj KA; Bowne WB; Adler V; Sarafraz-Yazdi E; Michl J; Pincus MR
Cancer Chemother Pharmacol; 2010 Jul; 66(2):325-31. PubMed ID: 20182728
[TBL] [Abstract][Full Text] [Related]
7. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.
Rosal R; Pincus MR; Brandt-Rauf PW; Fine RL; Michl J; Wang H
Biochemistry; 2004 Feb; 43(7):1854-61. PubMed ID: 14967026
[TBL] [Abstract][Full Text] [Related]
8. The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells.
Bowne WB; Sookraj KA; Vishnevetsky M; Adler V; Sarafraz-Yazdi E; Lou S; Koenke J; Shteyler V; Ikram K; Harding M; Bluth MH; Ng M; Brandt-Rauf PW; Hannan R; Bradu S; Zenilman ME; Michl J; Pincus MR
Ann Surg Oncol; 2008 Dec; 15(12):3588-600. PubMed ID: 18931881
[TBL] [Abstract][Full Text] [Related]
9. Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells.
Thadi A; Morano WF; Khalili M; Babcock BD; Shaikh MF; Foster DS; Piazza Y; Gleeson EM; Goldstein E; Steele L; Campbell PM; Lin BO; Pincus MR; Bowne WB
Anticancer Res; 2021 Jan; 41(1):27-42. PubMed ID: 33419797
[TBL] [Abstract][Full Text] [Related]
10. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.
Sarafraz-Yazdi E; Mumin S; Cheung D; Fridman D; Lin B; Wong L; Rosal R; Rudolph R; Frenkel M; Thadi A; Morano WF; Bowne WB; Pincus MR; Michl J
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625682
[TBL] [Abstract][Full Text] [Related]
11. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells.
Kanovsky M; Raffo A; Drew L; Rosal R; Do T; Friedman FK; Rubinstein P; Visser J; Robinson R; Brandt-Rauf PW; Michl J; Fine RL; Pincus MR
Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12438-43. PubMed ID: 11606716
[TBL] [Abstract][Full Text] [Related]
12. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site.
Do TN; Rosal RV; Drew L; Raffo AJ; Michl J; Pincus MR; Friedman FK; Petrylak DP; Cassai N; Szmulewicz J; Sidhu G; Fine RL; Brandt-Rauf PW
Oncogene; 2003 Mar; 22(10):1431-44. PubMed ID: 12629507
[TBL] [Abstract][Full Text] [Related]
13. P53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells.
Mokhtarzadeh A; Parhiz H; Hashemi M; Abnous K; Ramezani M
Expert Opin Drug Deliv; 2016; 13(4):477-91. PubMed ID: 26654047
[TBL] [Abstract][Full Text] [Related]
14. Structure of the stapled p53 peptide bound to Mdm2.
Baek S; Kutchukian PS; Verdine GL; Huber R; Holak TA; Lee KW; Popowicz GM
J Am Chem Soc; 2012 Jan; 134(1):103-6. PubMed ID: 22148351
[TBL] [Abstract][Full Text] [Related]
15. Anti-cancer peptides from ras-p21 and p53 proteins.
Pincus MR; Fenelus M; Sarafraz-Yazdi E; Adler V; Bowne W; Michl J
Curr Pharm Des; 2011; 17(25):2677-98. PubMed ID: 21728981
[TBL] [Abstract][Full Text] [Related]
16. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
[TBL] [Abstract][Full Text] [Related]
17. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.
Hu M; Gu L; Li M; Jeffrey PD; Gu W; Shi Y
PLoS Biol; 2006 Feb; 4(2):e27. PubMed ID: 16402859
[TBL] [Abstract][Full Text] [Related]
19. Use of a retroinverso p53 peptide as an inhibitor of MDM2.
Sakurai K; Chung HS; Kahne D
J Am Chem Soc; 2004 Dec; 126(50):16288-9. PubMed ID: 15600307
[TBL] [Abstract][Full Text] [Related]
20. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
